BridgeBio Oncology Therapeutics (BBOT) investor relations material

Executive summary

• Entered into multiple amendments to a Cooperative Research and Development Agreement (CRADA) with Lawrence Livermore National Security, LLC (LLNS) for the discovery of novel RAS inhibitors and P53 reactivators, extending the term through June 2027 and increasing total funding to $33.6 million.

• Reported meaningful progress across all three clinical programs targeting RAS-pathway malignancies, with encouraging preliminary safety and efficacy data for BBO-8520, BBO-11818, and BBO-10203.

• Announced publication in Cancer Discovery highlighting preclinical data for BBO-11818 as a potent and selective pan-KRAS inhibitor.

• Cash runway expected to fund operations into 2028, supported by $388.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

• Leadership changes include the appointment of a new CEO, COO, and Executive Chairman, as well as a new board member with significant oncology experience.

Significant events and developments

• The CRADA has been amended six times, each time extending the term and modifying the scope, deliverables, and funding levels, reflecting ongoing and expanding collaboration.

• The most recent amendment (Amendment Six) extends the CRADA to June 22, 2027, and increases the participant's estimated in-kind and funds-in contributions.

• The scope of work has evolved to include P53 reactivators in addition to RAS inhibitors.

• Publication of BBO-11818 preclinical data in Cancer Discovery.

• Appointment of Peter F. Lebowitz, MD, PhD, to the Board of Directors, and new executive leadership team announced.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $388.9 million as of March 31, 2026.

• Research and development expenses were $39.8 million for Q1 2026, up from $20.6 million in Q1 2025, mainly due to increased clinical and manufacturing activities.

• General and administrative expenses rose to $6.4 million from $2.5 million year-over-year, reflecting standalone operations and de-SPAC transaction.

• Net loss was $42.1 million for Q1 2026, compared to $22.1 million in Q1 2025.

• Net loss per share attributable to common stockholders was $(526.11) for Q1 2026, compared to $(54.23) for Q1 2025, reflecting a significant change in share count.